Oxidative stress and defective DNA repair are major contributory factors in the initiation and progression of carcinogenesis. Chemotherapy and radiotherapy cause oxidative DNA damage, consume antioxidant capacity, and impair DNA repair activity. These effects of chemotherapy and radiotherapy may be contributory factors in the development of secondary malignancy in cancer survivors. Basal, H2O2-induced, and postrepair DNA damage; urinary 8-hydroxydeoxyguanosine level as a marker of oxidatively damaged DNA; and serum total antioxidant capacity were measured; XPD Lys751Gln, XRCC1 Arg399Gln, and XRCC1 Arg194Trp polymorphisms were analyzed in childhood acute lymphoblastic leukemia (ALL) survivors. Basal and H2O2-induced DNA damage were found to be higher in the ALL survivor group versus the control group, however, there was no significant difference between the other parameters. No association was found between the examined parameters and polymorphisms of XPD 751 and XRCC1 399 and both the groups. XRCC1 194Trp allele was found to be associated with a low level of postrepair DNA damage in the ALL survivors. In conclusion, basal DNA damage and susceptibility to oxidation are high in childhood ALL survivors. This situation which may easily lead to occurrence of a secondary cancer does not seem to be a result of deficient DNA repair.
Silencing of the Cysteine dioxygenase-1 (CDO1) tumor suppressor gene by aberrant DNA methylation contributes to gastric carcinogenesis. Despite evidence that Helicobacter pylori (H. pylori) infection induces aberrant DNA methylation in the gastric mucosa, CDO1 promoter methylation has not been well characterized in H. Pylori positive (HPP) patients with chronic gastritis. This study aimed to investigate the CDO1 promoter methylation levels in patients with chronic gastritis with and without H. pylori infection, in comparison with gastric tumors. The quantitative analysis of CDO1 promoter methylation and CDO1 immunopositivity was performed in 45 primary gastric tumors, 17 biopsy samples of HPP chronic gastritis, 23 H. Pylori negative (HPN) chronic gastritis, and 15 normal gastric mucosa samples (control group). CDO1 expression was evaluated by immunohistochemistry, and promoter methylation levels were determined using quantitative methylation-specific PCR following bisulfite conversion. CDO1 promoter methylation levels were significantly higher in the gastric cancer (GC) group compared to the HPN chronic gastritis and control groups (p < 0.001). No significant difference was observed between the GC and HPP chronic gastritis groups. However, CDO1 promoter methylation levels were significantly higher in the HPP group compared to the HPN group (p = 0.049). No significant differences in CDO1 immunopositivity were observed among the study groups. ROC analysis demonstrated good discriminative ability of CDO1 methylation between GC and non-cancer cases (AUC = 0.83), whereas its performance was more limited in distinguishing GC from HPP chronic gastritis (AUC = 0.67). CDO1 promoter methylation is increased in GC and HPP chronic gastritis, suggesting that H. pylori -associated chronic inflammation may be associated with early epigenetic alterations. Although no direct correlation with protein expression was observed, our findings suggest that while CDO1 methylation may be informative for identifying cancer-related epigenetic changes, it may be insufficient as a standalone biomarker in high-risk inflammatory conditions. Further studies are needed to clarify its clinical utility, particularly in high-risk populations.
31 December 2017 in International Archives of Endocrinology Clinical Research
Beta cell death by apoptosis is an important mechanism in beta cell dysfunction and development of diabetes. Inhibition of apoptosis may be helpful approach in the prevention of diabetes. In this context, non-invasive, specific markers are needed to detect apoptosis in prediabetic stage. In the present study serum levels of cytokeratin-18/M30 antigen, a surrogate marker of apoptosis were investigated in cases with type 2 diabetes and İmpaired Glucose Tolerance (IGT).
Silencing of the Cysteine dioxygenase-1 (CDO1 ) tumor suppressor gene by aberrant DNA methylation contributes to gastric carcinogenesis. Despite earlier data indicating that Helicobacter pylori ( H. pylori ) infection induces aberrant DNA methylation in the gastric mucosa, the CDO1 methylation level has not been studied in H. pylori -positive (HPP) patients with chronic gastritis. This study aimed to investigate the CDO1 methylation level in patients with chronic gastritis who have and do not have H. pylori infection, in comparison to gastric tumours. The quantitative analysis of the promoter methylation of the CDO1 gene and CDO1 immunopositivity was determined in 45 primary gastric tumors, 17 biopsy samples of HPP- chronic gastritis, 23 H. pylori -negative (HPN) chronic gastritis, and 15 normal mucosa as the control. CDO1 expression levels were measured by immunohistochemical staining, and the methylation level of the promoter region was determined by quantitative methylation-specific PCR after bisulfite conversion. CDO1 gene promoter methylation levels were significantly higher in the gastric cancer (GC) group compared to the HPN-chronic gastritis and control groups (P = 0.000). There was no significant difference between the GC group and the HPP- chronic gastritis group. The CDO1 gene promoter methylation levels were higher in the HPP- chronic gastritis group than in the HPN-chronic gastritis group (P = 0.049). There was no significant difference between the study groups for the CDO1 immunopositivity score. The CDO1 gene promoter methylation levels are increased in GC and HPP-chronic gastritis patients. The CDO1 methylation, regardless of differences in protein expression, may be a promising non-invasive marker for early diagnosis of GC in HPP-chronic gastritis patients.